Market Report Source

Overview

Introduction

Keryx Biopharmaceuticals (Keryx) is a development stage company involved in acquiring, developing and commercializing products for diabetes and cancer. Sulonex, the company’s lead product candidate, is in Phase III/IV trials for diabetic nephropathy. In addition, Keryx is studying a renal therapeutic, Zerenex for hyperphosphatemmia in Phase II trials.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Keryx operates in three segments: diagnostics, services and products. The diagnostic division sells diagnostic products and began earning revenues from 2006. Services business involves clinical trial management and offers services to biotechnology and pharmaceutical companies. Keryx has been deriving service revenues since 2004. It’s total revenues decreased from $0.8 million to $0.4 million between 2004 and 2006. Keryx derived revenues from diagnostic product sales and service revenues. Diagnostic product sales recorded $0.1 million in 2006. Service revenues declined by 60% between 2004 and 2006, from $0.8 million to $0.4 million, due to the decrease in service contracts During 2006-2010, Keryx’s total revenues are expected to increase from $0.5 million to $182.7 million mainly due to the launch of Sulonex.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products and Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Product Development
Scorecard
Overview
Scorecard analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Keryx Biopharmaceuticals – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Keryx Biopharmaceuticals – Key Strategic Revenues, 2002-2006 ($ Mn)
Figure 3: Keryx Biopharmaceuticals – Key Strategic Revenues, 2006-2010 ($ Mn)

TABLES
Table 1: Keryx Biopharmaceuticals – Key Facts
Table 2: Keryx Biopharmaceuticals – Locations and Subsidiaries
Table 3: Keryx Biopharmaceuticals – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Keryx Biopharmaceuticals – Key Events Impacting Share Price Performance
Table 5: Keryx Biopharmaceuticals – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: Keryx Biopharmaceuticals – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Keryx Biopharmaceuticals – Balance Sheet
Table 8: Keryx Biopharmaceuticals – Cash Flow
Table 9: Keryx Biopharmaceuticals – Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 10: Keryx Biopharmaceuticals – In-house Pipeline Products
Table 11: Keryx Biopharmaceuticals – Forecast Sales, 2006-2010 ($ Mn)
Table 12: Keryx Biopharmaceuticals – Key Competitors
Table 13: Keryx Biopharmaceuticals – Key Suppliers
Table 14: Keryx Biopharmaceuticals – Key Shareholders
Table 15: Keryx Biopharmaceuticals – SWOT Analysis Summary
Table 16: Keryx Biopharmaceuticals – Value Chain Analysis
Table 17: Keryx Biopharmaceuticals – Scorecard
Table 18: Keryx Biopharmaceuticals – Key Employees
Table 19: Keryx Biopharmaceuticals- Financial and Operational Overview